‘Manufacturing process a must for Sinovac vaccine’


Senior Minister (Security Cluster) Datuk Seri Ismail Sabri Yaakob (front, second right) receives a package containing Sinovic vaccines from China’s Ambassador to Malaysia, Ouyang Yujing, at the KLIA. Also present are Khairy (front, left) and Foreign Minister Datuk Seri Hishamuddin Tun Hussein (front, right). — Bernama photo

KUALA LUMPUR: The China’s Sinovac Covid-19 vaccine received by Malaysia must first go through a manufacturing process by the pharmaceutical company, Pharmaniaga, to be evaluated and approved by the regulatory agency.

Coordinating Minister for the National Covid-19 Immunisation Programme, Khairy Jamaluddin, said the manufacturing process was one of the criteria that would be evaluated by the National Pharmaceutical Regulatory Agency (NPRA) before giving recommendations to the Drug Control Authority (PBKD) for approval.

“Many ask why we receive a vaccine that has yet to be approved by the regulatory today. This is because the approval process from the regulatory must look at how this vaccine is bottled before it can be approved.”

He said this, among other things, aimed to provide registration application data and to carry out validation process as well as looking at the stability data from the factory.

Khairy, who is the Minister of Science, Technology and Innovation, said this during a press conference held after witnessing the arrival of the 200 litres of Sinovac vaccine, developed by the Chinese pharmaceutical firm, at the Kuala Lumpur International Airport (KLIA) from Beijing, China, yesterday morning.

The minister stressed that the evaluation process was to ensure that the vaccine bottled at the Pharmaniaga plant would be similar, in terms of quality and potential, to those manufactured in China.

“This will allow the data of clinical trials on humans conducted using products produced by manufacturers in China to be used by Pharmaniaga to support their products to be safe and effective,” he said.

He also explained that the vaccine was received in advance by Malaysia even though it had yet to be given approval by the national regulatory body due to limited supply of the world’s Covid-19 vaccine.

Khairy said, for example, Singapore also received the vaccine in the form of a finished product even though it had yet to receive approval from the country’s regulatory body.

“We want to make sure that even though regulatory approval has not been given, we give permission to bring in (Sinovac vaccine) so that stability testing can be tested at the factory.

“Once it is given approval by NPRA and PBKD, the vaccine is already here so it will be easy for us to continue,” he said.

“I was informed that Pharmaniaga could produce two million doses (of Sinovac) every month at its factory in Puchong – meaning that we would have a steady supply from Pharmaniaga,” he said.

Asked to comment on the Sinovac vaccine approval date, Khairy said it would be up to the Ministry of Health Malaysia (MoH) and NPRA.

“I do not know and I cannot know because NPRA works independently and neutrally, and I cannot ask when they would approve it.

“They must be allowed to do the work.

“Of course, we want them to approve it safe and as quickly as possible but there is no short cut,” he said.

On whether approval for Sinovac vaccine registration should be done every time the vaccine group was received from China, Khairy said it would only be implemented once.

“If NPRA is satisfied with the vaccine we have received today (yesterday) as well as the manufacturing process and also the stability testing implemented (by Pharmaniaga), then it would be given approval and to be registered, perhaps, with the conditional registration, similar to Pfizer.”

On media reports that the US Food and Drug Administration (FDA) approved the storage of the Covid-19 Pfizer vaccine at -20ºC from -70ºC  to -80ºC previously, Khairy confirmed the matter.

“What Pfizer will have to do now is to submit to NPRA the new data that show the vaccine is stable for two weeks at -20ºC for NPRA’s approval. Although we have agreed with the FDA, we have to approve it here,” he said.

On the status of vaccine acquisition from Johnson & Johnson, Khairy said the MoH was refining the term sheet from the company and he had requested that it be signed by Health Minister Datuk Seri Dr Adham Baba in the near future.

Meanwhile, Khairy said a total of 1.183 million registrations to receive the vaccine were recorded on the MySejahtera application, and a total of 3,580 individuals had received vaccine shot as at 7am yesterday. — Bernama